OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
BANB58

BANB.S

Biotechnology & Medical ResearchVerified

BANB.S maintains a strong liquidity position with a current ratio of 1.79, indicating the company can cover its short-term liabilities with its short-term assets. However, the company has a negative net cash position after subtracting total debt, which raises liquidity concerns. The debt-to-equity ratio is 0.04, suggesting a conservative capital structure with minimal leverage. In terms of profitability, BANB.S reports a return on equity (ROE) of 10.2% and a return on assets (ROA) of 7.06%, both of which are strong indicators of efficient use of equity and assets. The company's operating income of CHF 167.3 million and net income of CHF 148.8 million reflect solid operational performance. Gross profit of CHF 199.7 million further supports the company's ability to generate profit from its core operations. BANB.S does not disclose specific segment or geographic revenue breakdowns in the provided data, making it difficult to assess revenue concentration or geographic exposure. Analysts have not provided detailed segment outlooks, so the company's performance across different business lines remains unclear. Looking at the growth trajectory, BANB.S has a revenue of CHF 695.07 million, but the provided data does not include historical revenue figures or future growth projections. Analysts have assigned a mean price target of CHF 79.12 and a median price target of CHF 80.00, with a mean recommendation of 2.80, indicating a generally positive outlook. The risk assessment for BANB.S highlights a medium liquidity risk and a low dilution risk. The company's free cash flow is negative at CHF -154.06 million, and capital expenditures are CHF -319.56 million, indicating significant investment in long-term assets. The negative net cash position after subtracting total debt is a key flag that may impact the company's liquidity. Recent events and filings for BANB.S are not detailed in the provided data, so there is no specific information on recent corporate actions or strategic developments. Analysts have issued five "Buy" and three "Hold" recommendations, with no "Strong Buy" ratings, suggesting a cautious but generally positive sentiment.

30-day price · BANB+13.35 (+20.1%)
Low$64.25High$83.25Close$79.70As of26 May, 00:00 UTC
Profile
CompanyBANB.S
TickerBANB.S
SectorHealthcare
BusinessPharmaceuticals & Medical Research
Industry groupPharmaceuticals & Medical Research
IndustryBiotechnology & Medical Research
AI analysis

Business. BANB.S operates in the healthcare diagnostics industry, providing products and services related to medical research and diagnostics.

Classification. BANB.S is classified under the Healthcare economic sector, within the Pharmaceuticals & Medical Research business sector, with a confidence level of 0.92.

BANB.S maintains a strong liquidity position with a current ratio of 1.79, indicating the company can cover its short-term liabilities with its short-term assets. However, the company has a negative net cash position after subtracting total debt, which raises liquidity concerns. The debt-to-equity ratio is 0.04, suggesting a conservative capital structure with minimal leverage. In terms of profitability, BANB.S reports a return on equity (ROE) of 10.2% and a return on assets (ROA) of 7.06%, both of which are strong indicators of efficient use of equity and assets. The company's operating income of CHF 167.3 million and net income of CHF 148.8 million reflect solid operational performance. Gross profit of CHF 199.7 million further supports the company's ability to generate profit from its core operations. BANB.S does not disclose specific segment or geographic revenue breakdowns in the provided data, making it difficult to assess revenue concentration or geographic exposure. Analysts have not provided detailed segment outlooks, so the company's performance across different business lines remains unclear. Looking at the growth trajectory, BANB.S has a revenue of CHF 695.07 million, but the provided data does not include historical revenue figures or future growth projections. Analysts have assigned a mean price target of CHF 79.12 and a median price target of CHF 80.00, with a mean recommendation of 2.80, indicating a generally positive outlook. The risk assessment for BANB.S highlights a medium liquidity risk and a low dilution risk. The company's free cash flow is negative at CHF -154.06 million, and capital expenditures are CHF -319.56 million, indicating significant investment in long-term assets. The negative net cash position after subtracting total debt is a key flag that may impact the company's liquidity. Recent events and filings for BANB.S are not detailed in the provided data, so there is no specific information on recent corporate actions or strategic developments. Analysts have issued five "Buy" and three "Hold" recommendations, with no "Strong Buy" ratings, suggesting a cautious but generally positive sentiment.
Key takeaways
  • BANB.S has a strong ROE of 10.2% and ROA of 7.06%, indicating efficient use of equity and assets.
  • The company maintains a conservative capital structure with a debt-to-equity ratio of 0.04.
  • BANB.S has a current ratio of 1.79, suggesting it can cover its short-term liabilities with its short-term assets.
  • Analysts have assigned a mean price target of CHF 79.12 and a median price target of CHF 80.00, with a mean recommendation of 2.80.
  • The company has a negative net cash position after subtracting total debt, which raises liquidity concerns.
  • --
  • # RATIONALES
  • ```json
Financial snapshot
PeriodHA-latest
CurrencyCHF
Revenue$695.1M
Gross profit$199.7M
Operating income$167.3M
Net income$148.8M
R&D
SG&A
D&A
SBC
Operating cash flow$271.6M
CapEx-$319.6M
Free cash flow-$154.1M
Total assets$2.11B
Total liabilities$650.4M
Total equity$1.46B
Cash & equivalents
Long-term debt$57.4M
Valuation
Market price
Market cap
Enterprise value
P/E
Reported non-GAAP P/E
EV/Revenue
EV/Op income
EV/OCF
P/B
P/Tangible book
Tangible book$1.46B
Net cash-$57.4M
Current ratio1.8
Debt/Equity0.0
ROA7.1%
ROE10.2%
Cash conversion1.8%
CapEx/Revenue-46.0%
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskMedium
  • Net cash is negative after subtracting total debt.
Industry benchmarks
Activity: Healthcare Diagnostics · cohort 170 companies
MetricBANBActivity
Op margin24.1%-227.5% medp25 -1250.6% · p75 -3.5%top quartile
Net margin21.4%-194.5% medp25 -1233.8% · p75 0.8%top quartile
Gross margin28.7%53.0% medp25 25.9% · p75 75.7%below median
CapEx / revenue-46.0%-8.2% medp25 -35.2% · p75 -2.5%bottom quartile
Debt / equity4.0%1.2% medp25 0.0% · p75 17.4%above median
Observations
IR observations
Mean price target79.12 CHF
Median price target80.00 CHF
High price target110.00 CHF
Low price target46.00 CHF
Mean recommendation2.80 (1=strong buy, 5=strong sell)
Strong-buy count0.00
Buy count5.00
Hold count3.00
Sell count1.00
Strong-sell count1.00
Mean EPS estimate2.42 CHF
Last actual EPS1.98 CHF
Source data
Underlying data the analysis-pipeline pulls and audits. Fetch timestamps + content hashes show when each source was last refreshed.
Company fundamentalsperiod FQ-7 · history via verified-market-data
no public URL
2026-05-06 17:13 UTC#c4a7d927
Source: analysis-pipeline (hybrid)Generated: 2026-05-27 11:03 UTCJob: a5a422b7